Novo Nordisk has expanded its collaboration with Valo Health, a Flagship Pioneering company, to leverage artificial intelligence in drug discovery for obesity and diabetes. The partnership aims to accelerate the identification and development of novel therapies by combining Novo Nordisk’s expertise in metabolic diseases with Valo Health’s AI-driven platform. This move reflects the growing trend of integrating AI in pharmaceutical research to tackle complex conditions. Could this be the breakthrough needed to transform diabetes and obesity management?
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes (Fierce Healthcare)
0